The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 3, 2000, Pages 277-284

  McClanahan, Thomas B ^a,b   Hicks, Gary W ^a,b   Ignasiak, Diane P ^a,b   Bousley, Richard ^a,b   Mertz, Thomas E ^a,b   Juneau, Paul ^a,b   Janiczek Dolphin, Nancy ^a,b   Kim, In Chull ^a,b   Gallagher, Kim P ^a,b  

^a PFIZER INC   (United States)

^b LG Chemical Ltd   (South Korea)

Author keywords

Electrolytic injury; Thrombin inhibition; Thrombosis

Indexed keywords

CI 1028; LB 30057; PD 172524; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; ELECTRIC INJURY; FEMALE; MALE; NONHUMAN; OCCLUSION; PRIORITY JOURNAL; VEIN BLOOD FLOW; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BENZAMIDES; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION TESTS; BLOOD FLOW VELOCITY; BLOOD LOSS, SURGICAL; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEMORRHAGE; THROMBIN; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0034526532     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026555510258     Document Type: Article

References (25)

1. Thrombosis in ischemic heart disease
2. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism
3. Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals
4. Management of venous thrombolembolism
5. Oral anticoagulant drugs
6. Thrombosis and the pharmacology of antithrombotic agents
7. New anticoagulant strategies
8. Oral anticoagulants: Pharmacodynamics, clinical indications and adverse effects
9. Low-molecular weight heparin: A review of the results of recent studies of the treatment of venous thrombolism and unstable angina
10. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction
11. Direct thrombin inhibitors in cardiovascular disease
12. Direct thrombin inhibitors in cardiovascular medicine
13. Potential advantages of direct-acting thrombin inhibitors
14. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor
15. Structural modification of an orally active thrombin inhibitor, LB30057: Replacement of the D-pocket-binding naphthyl moiety
16. Discovery of a highly selective, orally bioavailable, direct thrombin inhibitor, LB30057
17. The antithrombotic effects of LB30057 in a canine model of electrolytically induced venous thrombosis
18. Mechanisms of arterial thrombosis: Foundation for therapy
19. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: A comparison with heparin
20. Heparin mechanism of action, pharmacokinetics, dosing consideration, monitoring, efficacy, and safety
21. Melagatran, An oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
22. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog
23. Thrombin hypothesis: The TIMI 9B and Gusto IIB trials have successfully disproven/proven the thrombin hypothesis
24. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, RO 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis
25. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement